In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Cubist, Emisphere partner in oral delivery of daptomycin

Executive Summary

Antimicrobial drug developer Cubist Pharmaceuticals will license oral drug delivery technology from Emisphere Technologies (oral delivery of large-molecule drugs) to apply to its Phase III antibiotic Cidecin (daptomycin), currently an injectable product, and other lipopeptides.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • R+D and Marketing-Licensing
    • Intra-Biotech Deal

Related Companies

Advertisement
UsernamePublicRestriction

Register